Abstract
ABSTRACT Inhaled budesonide has been shown to be an effective therapy for asthma. In a previous study in a sheep model, acute treatment with budesonide delivered by pressurized metered dose inhaler (pMDI) modified the late bronchoconstrictor response to inhaled antigen. In the present study, we utilized the same sheep model to assess whether the delivery of budesonide in a liposome preparation would modify the late asthmatic response and the associated airway hyperresponsiveness that is detectable 24 hours after challenge. In a crossover trial, six conscious intubated sheep were pretreated with 1 mg of budesonide/dilauroyl phosphatidylcholine (DLPC), or DLPC alone, 16 hours and again 1 hour prior to the administration of aerosolized Ascaris suum antigen. Using esophageal and tracheal pressure measurements and plethysmography, specific lung resistance (sRL) was measured over an 8-hour period following administration of the antigen. In addition, airway responsiveness to carbachol (as assessed by potential d...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
